173 related articles for article (PubMed ID: 29943287)
1. Investigation of the effect of homocysteinylation of substance P on its binding to the NK1 receptor using molecular dynamics simulation.
Davoudmanesh S; Mosaabadi JM
J Mol Model; 2018 Jun; 24(7):177. PubMed ID: 29943287
[TBL] [Abstract][Full Text] [Related]
2. N- and C-terminal substance P fragments: differential effects on striatal [3H]substance P binding and NK1 receptor internalization.
Michael-Titus AT; Blackburn D; Connolly Y; Priestley JV; Whelpton R
Neuroreport; 1999 Jul; 10(10):2209-13. PubMed ID: 10424700
[TBL] [Abstract][Full Text] [Related]
3. Point mutation increases a form of the NK1 receptor with high affinity for neurokinin A and B and septide.
Ciucci A; Palma C; Manzini S; Werge TM
Br J Pharmacol; 1998 Sep; 125(2):393-401. PubMed ID: 9786514
[TBL] [Abstract][Full Text] [Related]
4. Systematic study of substance P analogs. II. Rapid screening of 512 substance P stereoisomers for binding to NK1 receptor.
Wang JX; Dipasquale AJ; Bray AM; Maeji NJ; Spellmeyer DC; Geysen HM
Int J Pept Protein Res; 1993 Oct; 42(4):392-9. PubMed ID: 7503964
[TBL] [Abstract][Full Text] [Related]
5. Mapping substance P binding sites on the neurokinin-1 receptor using genetic incorporation of a photoreactive amino acid.
Valentin-Hansen L; Park M; Huber T; Grunbeck A; Naganathan S; Schwartz TW; Sakmar TP
J Biol Chem; 2014 Jun; 289(26):18045-54. PubMed ID: 24831006
[TBL] [Abstract][Full Text] [Related]
6. Calpha methylation in molecular recognition. Application to substance P and the two neurokinin-1 receptor binding sites.
Sagan S; Lequin O; Frank F; Convert O; Ayoub M; Lavielle S; Chassaing G
Eur J Biochem; 2001 May; 268(10):2997-3005. PubMed ID: 11358518
[TBL] [Abstract][Full Text] [Related]
7. Recognition of neurokinin 1 receptor (NK1-R): an antibody to a peptide sequence from the third extracellular region binds to brain NK1-R.
van Ginkel FW; Pascual DW
J Neuroimmunol; 1996 Jun; 67(1):49-58. PubMed ID: 8707930
[TBL] [Abstract][Full Text] [Related]
8. Septide: an agonist for the NK1 receptor acting at a site distinct from substance P.
Pradier L; Ménager J; Le Guern J; Bock MD; Heuillet E; Fardin V; Garret C; Doble A; Mayaux JF
Mol Pharmacol; 1994 Feb; 45(2):287-93. PubMed ID: 7509440
[TBL] [Abstract][Full Text] [Related]
9. Radioiodinated substance P, neurokinin A, and eledoisin bind predominantly in NK1 receptors in guinea pig lung.
Geraghty DP; Mussap CJ; Burcher E
Mol Pharmacol; 1992 Jan; 41(1):147-53. PubMed ID: 1370705
[TBL] [Abstract][Full Text] [Related]
10. Differential activation of the epithelial and smooth muscle NK1 receptors by synthetic tachykinin agonists in guinea-pig trachea.
Figini M; Emanueli C; Bertrand C; Sicuteri R; Regoli D; Geppetti P
Br J Pharmacol; 1997 Jun; 121(4):773-81. PubMed ID: 9208147
[TBL] [Abstract][Full Text] [Related]
11. Comparative, general pharmacology of SDZ NKT 343, a novel, selective NK1 receptor antagonist.
Walpole CS; Brown MC; James IF; Campbell EA; McIntyre P; Docherty R; Ko S; Hedley L; Ewan S; Buchheit KH; Urban LA
Br J Pharmacol; 1998 May; 124(1):83-92. PubMed ID: 9630347
[TBL] [Abstract][Full Text] [Related]
12. Binding of substance P agonists to lipid membranes and to the neurokinin-1 receptor.
Seelig A; Alt T; Lotz S; Hölzemann G
Biochemistry; 1996 Apr; 35(14):4365-74. PubMed ID: 8605185
[TBL] [Abstract][Full Text] [Related]
13. The NK1 receptor and its participation in the synergistic enhancement of corneal epithelial migration by substance P and insulin-like growth factor-1.
Nakamura M; Ofuji K; Chikama T; Nishida T
Br J Pharmacol; 1997 Feb; 120(4):547-52. PubMed ID: 9051288
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure of the human NK
Yin J; Chapman K; Clark LD; Shao Z; Borek D; Xu Q; Wang J; Rosenbaum DM
Proc Natl Acad Sci U S A; 2018 Dec; 115(52):13264-13269. PubMed ID: 30538204
[TBL] [Abstract][Full Text] [Related]
15. Kinetic binding and activation profiles of endogenous tachykinins targeting the NK1 receptor.
Nederpelt I; Bleeker D; Tuijt B; IJzerman AP; Heitman LH
Biochem Pharmacol; 2016 Oct; 118():88-95. PubMed ID: 27501920
[TBL] [Abstract][Full Text] [Related]
16. Substance P and neurokinin 1 receptor are new targets for the treatment of chronic pruritus.
Ständer S; Yosipovitch G
Br J Dermatol; 2019 Nov; 181(5):932-938. PubMed ID: 31016733
[TBL] [Abstract][Full Text] [Related]
17. From the Anti-Nociceptive Substance P Metabolite Substance P (1-7) to Small Peptidomimetics.
Hallberg M; Sandstrom A
Curr Protein Pept Sci; 2018; 19(11):1038-1048. PubMed ID: 29745331
[TBL] [Abstract][Full Text] [Related]
18. The use of photolabelled peptides to localize the substance-P-binding site in the human neurokinin-1 tachykinin receptor.
Girault S; Sagan S; Bolbach G; Lavielle S; Chassaing G
Eur J Biochem; 1996 Aug; 240(1):215-22. PubMed ID: 8797856
[TBL] [Abstract][Full Text] [Related]
19. Neurokinin receptors (NK1, NK2) in the mouse: a pharmacological study.
Nsa Allogho S; Nguyen-Le XK; Gobeil F; Pheng LH; Regoli D
Can J Physiol Pharmacol; 1997 Jun; 75(6):552-7. PubMed ID: 9276127
[TBL] [Abstract][Full Text] [Related]
20. Receptors mediating tachykinin-evoked depolarisations of neurons in the neonatal rat spinal cord.
Fox AJ; Naeem S; Patel IA; Walpole C; Urbán L
Acta Biol Hung; 1996; 47(1-4):129-44. PubMed ID: 9123986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
